Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors
Tumor Agnostic Development
Accelerated Development Paths
Multifunctional Soluble Biologics: Binders, Binders Everywhere
ACT for Solid Tumors
Validating Novel Cell Therapy Platforms
“It’s an Allo Thing”
Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML
Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?
...More panels TDB
Cancer Progress 2020 Panel Summaries
As a preview of the good things to expect from Cancer Progress 2021, we’re excited to roll out summaries of select sessions from Cancer Progress 2020, starting with a summary of the panel “Paradigm Shifting Platforms II – Non-IO: Targeting Better, Targeting the Intractable” that highlights the key opportunities and challenges of non-IO targeted approaches and how even they cannot be thought of independently from IO.
Good array of opinions and technologies. Well curated
Andrew Allen, MD, PhD, President & CEOGritstone Oncology
As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!
Michael G. King, Jr., Entrepreneur in ResidenceFortress Biotech Inc.
When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts
Mark Simon, Managing DirectorTorreya
“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”